EUVIMEDEUVIMED entdecken
Open Access

Resistance to anti-TB drugs: evaluation of universal resistance surveillance implementation in Chile

G N Barra, M Oyarte, K K Ivani, Á D Briceño, I M Espinoza, T L Calderón, M M Juica, A S Bordón, J F Oviedo, F A Muñoz

IJTLD Open · 2026-06 · 3 (6) · 384-390

DOI: 10.5588/ijtldopen.25.0507 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IJTLD Open, online erschienen am 01.06.2026. Verfasst von G N Barra und 9 weiteren Autor:innen. Beteiligte Einrichtung: Departamento Biomédico Nacional y de Referencia, Instituto de Salud Pública de Chile, Unidad de Investigación EInnovación. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND TB remains a public health challenge in Chile, where all bacteriologically confirmed TB cases are tested for drug susceptibility at the National Reference Laboratory of the Instituto de Salud Pública (ISP). OBJECTIVE We evaluated the impact of implementing universal surveillance for rifampicin and isoniazid resistance in Chile and described resistance profiles and epidemiological factors. DESIGN Retrospective analysis of drug susceptibility testing (DST) results from Mycobacterium tuberculosis cultures processed at the ISP between 2003 and 2020. DST was performed using line probe assays and mycobacteria growth indicator tube liquid culture. Demographic and clinical data were analysed, and a negative binomial regression model assessed changes before and after universal surveillance in 2014 (2003–2014 vs. 2015–2020). RESULTS Among 44,800 isolates analysed, 911 had first-line resistance to isoniazid or rifampicin: 377 showed isoniazid monoresistance, 155 rifampicin monoresistance, 378 multidrug resistance, and one extensively drug-resistant case. Detection of resistant cases increased after universal surveillance (incidence rate ratio = 3.592, P < 0.001). Resistance was most frequent in men aged 16–64 and in the central macrozone. CONCLUSION Universal surveillance improved detection of drug-resistant TB in Chile, supporting its value for timely treatment adaptation and targeted public health strategies, especially in high-risk demographic and geographic groups.

Schlagwörter

Stichwörter der Autor:innen

MDR-TBdrug susceptibility testingepidemiological surveillanceline probe assaytuberculosis

Autor:innen und Institutionen

  • Departamento Biomédico Nacional y de Referencia, Instituto de Salud Pública de Chile, Unidad de Investigación EInnovación.
  • Sección Micobacterias, Departamento Biomédico Nacional y de Referencia, Instituto de Salud Pública de Chile, Santiago, Chile.

Zitieren

APA

Barra, G. N., Oyarte, M., Ivani, K. K., Briceño, Á. D., Espinoza, I. M., Calderón, T. L., Juica, M. M., Bordón, A. S., Oviedo, J. F., & Muñoz, F. A. (2026). Resistance to anti-TB drugs: evaluation of universal resistance surveillance implementation in Chile. IJTLD Open, 3(6), 384-390. https://doi.org/10.5588/ijtldopen.25.0507

Vancouver

Barra GN, Oyarte M, Ivani KK, Briceño ÁD, Espinoza IM, Calderón TL, et al. Resistance to anti-TB drugs: evaluation of universal resistance surveillance implementation in Chile. IJTLD Open. 2026;3(6):384-390. doi:10.5588/ijtldopen.25.0507

BibTeX
@article{Barra2026,
  author = {Barra, G N and Oyarte, M and Ivani, K K and Briceño, Á D and Espinoza, I M and Calderón, T L and Juica, M M and Bordón, A S and Oviedo, J F and Muñoz, F A},
  title = {Resistance to anti-TB drugs: evaluation of universal resistance surveillance implementation in Chile},
  journal = {IJTLD Open},
  year = {2026},
  volume = {3},
  number = {6},
  pages = {384--390},
  doi = {10.5588/ijtldopen.25.0507}
}
Kostenlos starten →